一、监事会会议召开情况 嘉必优生物技术(武汉)股份有限公司（以下简称"公司"）第四届监事会第 九次会议（以下简称"本次会议"）于 2025 年 9 月 8 日以现场结合通讯形式召开。 会议通知已于 2025 年 9 月 5 日通过邮件方式送达全体监事。本次会议应出席监 事 3 人，实际出席监事 3 人，会议由监事会主席王纪召集并主持。本次会议的 召集、召开和表决程序符合有关法律法规、规范性文件和《公司章程》的规定。 二、监事会会议审议情况 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688089 证券简称：嘉必优 公告编号：2025-070 嘉必优生物技术（武汉）股份有限公司 第四届监事会第九次会议决议公告 经与会监事审议表决，通过了以下议案： 议案一、审议通过《关于调整第二期以集中竞价方式回购股票价格上限的 议案》 经审议，监事会认为：公司本次调整第二期回购股份价格上限，是基于市 场动态和公司经营情况，维护公司市场价值，传递公司发展信心的合理举措， 不存在损害全体股东特别是中小股东利益的情形，同意本次议案。 ...

经过与会董事审议表决，形成如下决议： 议案一、审议通过了《关于调整第二期以集中竞价方式回购股票价格上限 的议案》 经审议，董事会认为：公司本次调整第二期回购股份价格上限，是基于市 场动态和公司经营情况，维护公司市场价值，传递公司发展信心的合理举措， 不存在损害全体股东特别是中小股东利益的情形，同意本次议案。 表决结果：9 票同意，0 票反对，0 票弃权。 具体内容详见公司同日在上海证券交易所网站（www.sse.com.cn）披露的 《嘉必优生物技术（武汉）股份有限公司关于调整第二期以集中竞价方式回购 公司股份价格上限的公告》（公告编号：2025-069）。 证券代码：688089 证券简称：嘉必优 公告编号：2025-071 嘉必优生物技术（武汉）股份有限公司 第四届董事会第九次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 嘉必优生物技术(武汉)股份有限公司（以下简称"公司"）于 2025 年 9 月 8 日以现场结合通讯形式召开第四届董事会第九次会议。会议通知已于 2025 年 ...

Core Viewpoint - The company, Jia Bi You, announced its participation in the 2025 semi-annual performance briefing for the bioproducts and CXO industry, organized by the Shanghai Stock Exchange, scheduled for September 15, 2025, from 15:00 to 17:00 [2] Group 1 - The company plans to attend a collective performance briefing [2] - The event is focused on the bioproducts and CXO industry [2] - The briefing is organized by the Shanghai Stock Exchange [2]

Group 1 - The company will hold a performance briefing for the first half of 2025 on September 15, 2025, from 15:00 to 17:00 [1][2] - The meeting will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online text interaction format [1][2] - Investors can submit questions from September 8 to September 12, 2025, through the Roadshow Center website or via the company's email [1][3] Group 2 - Key personnel attending the meeting include the Chairman and General Manager, Yi Dewei, and the Financial Director, Wang Huabiao [2] - The company aims to address common investor concerns regarding its operational results and financial indicators during the briefing [2][3] - After the meeting, investors can access the main content and outcomes of the briefing on the Roadshow Center website [3]

证券代码：688089 证券简称：嘉必优 公告编号：2025-068 嘉必优生物技术（武汉）股份有限公司 关于参加 2025年半年度科创板生物制品及CXO行业集体业 绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： （网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2025 年 09 月 08 日（星期一）至 09 月 12 日（星期五）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 zqb@cabio.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 嘉必优生物技术（武汉）股份有限公司(以下简称"公司")已于 2025 年 8 月 19 日发布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 09 月 15 日（星期一） 15:00-17:00参加由上海证券交易所主办的2025年半年度科创板生物制品及 ...

Fundraising Overview - The company has successfully completed an initial public offering (IPO) of 30,000,000 shares at a price of RMB 23.90 per share, raising a total of RMB 717 million, with a net amount of RMB 648.33 million after deducting issuance costs [1][2] Fund Management and Usage - The company has established a management system for the use and management of the raised funds, ensuring compliance with regulations and protecting investor rights [2] - A tripartite supervision agreement has been signed with the underwriter and the banks to ensure that the funds are used specifically for their intended purposes [2] Account Closure - The company has closed a special account for the raised funds at China Merchants Bank, as the funds in that account have been fully utilized according to regulations [3]

Core Viewpoint - Jia Bi You announced that as of August 31, 2025, the company has not repurchased any shares through the dedicated repurchase account [1] Group 1 - The announcement was made on the evening of September 3 [1] - The company has a dedicated repurchase account for share buybacks [1]

数据显示，9月1日至3日，嘉必优的股价持续下跌。有投资者提问，"公司股价走势本来就很弱，现在终 止收购，股价又大跌，造成很多投资者损失，公司会采取什么措施提升投资者信心？" 对此，嘉必优表示："公司终止本次筹划重大资产重组事项是经过审慎考虑的决定，是对公司和投资者 负责的决策。未来，公司将保持战略定力，稳步推进各项工作，通过技术创新不断开发高附加值应用新 场景，做大做强公司业绩，同时也将积极吸取广大投资者的建议与意见，加强资本市场沟通，切实守护 全体投资者利益。" 另外，嘉必优还提到，"公司与欧易已经开展的合作将持续深入推进，未来将根据公司战略和业务发展 的需求，探讨更多合作机会。" 9月3日，嘉必优披露投资者活动记录表。在与投资者交流过程中，嘉必优介绍，公司综合考虑市场环境 及标的公司的业务运行情况较本次交易筹划初期已发生一定变化，为切实维护公司和广大投资者的利 益，经审慎研究，决定终止收购欧易生物的股权。 记者注意到，嘉必优从去年便开始筹划收购欧易生物部分股权一事，其间两度调整交易方案，还曾被上 海证券交易所问询。最新方案显示，嘉必优拟收购欧易生物63.2134%的股权，交易价格约8.31亿元。本 次交易 ...

Group 1 - The core point of the article is that the company Jia Biyou has decided to terminate the acquisition of a stake in Ouyi Biological due to changes in market conditions and the operational status of the target company, which was a shift from the initial planning stage [1] - Jia Biyou had been planning the acquisition since last year, with two adjustments to the transaction plan and inquiries from the Shanghai Stock Exchange [1] - The latest plan indicated that Jia Biyou intended to acquire 63.2134% of Ouyi Biological for approximately 831 million yuan, with a premium rate of 441.23% [1] Group 2 - Following the announcement of the termination, Jia Biyou's stock price experienced a continuous decline from September 1 to September 3, raising concerns among investors about potential losses [2] - In response to investor concerns, Jia Biyou stated that the decision to terminate the acquisition was made after careful consideration and was aimed at protecting the interests of the company and its investors [2] - The company emphasized its commitment to maintaining strategic focus, advancing technological innovation, and exploring further cooperation opportunities with Ouyi Biological in the future [2]

Core Points - Jia Bi You (688089.SH) announced that as of August 31, 2025, the company has not repurchased its shares through a dedicated repurchase account [1]